Abelacimab Shows Low Bleeding Rates in Phase 2 Periprocedural Trial, May Simplify Anticoagulation Management
核心洞察
The AZALEA-TIMI 71 Phase 2 trial demonstrated that abelacimab, a long-acting factor XI (搜索) inhibitor, is associated with low periprocedural bleeding (搜索) rates across various surgical procedures.
Despite abelacimab's 28-day half-life and prolonged pharmacodynamic effects, bleeding (搜索) rates were comparable to rivaroxaban, with most bleeding events occurring within 7 days of procedures.
The findings suggest potential for simplified periprocedural anticoagulation protocols, possibly eliminating the need to interrupt abelacimab for all but the highest bleeding (搜索) risk procedures.
A Phase 2 clinical trial has demonstrated that abelacimab, a long-acting factor XI (搜索) inhibitor developed by Anthos Therapeutics (搜索), maintains low periprocedural bleeding (搜索) rates despite its extended half-life, potentially revolutionizing anticoagulation management for patients undergoing elective and urgent medical procedures. The findings from the AZALEA-TIMI 71 trial (NCT04755283) were presented by Jeffrey I. Weitz, MD, at the International Society on Thrombosis (搜索) and Haemostasis (ISTH) 2025 Congress in Washington, DC.
Trial Design and Risk Stratification
The AZALEA-TIMI 71 study evaluated the periprocedural safety of abelacimab in patients undergoing invasive procedures while on anticoagulation therapy. Researchers stratified procedural bleeding (搜索) risk as low, moderate, or high using guidance from the 2017 American College of Cardiology expert consensus decision pathway for periprocedural management of anticoagulants, ensuring consistency with current clinical guidelines.
The trial included 59 high-risk bleeding (搜索) procedures, comprising major orthopedic surgery (32.2%), spinal surgery (30.5%), abdominal surgery (11.9%), procedures involving large bore vascular access (8.5%), cardiac surgery (3.4%), and other high-risk or open surgery (13.6%). Most patients, however, underwent procedures associated with low or moderate bleeding risk.
Pharmacokinetic Profile and Clinical Outcomes
Abelacimab demonstrates unique pharmacokinetic properties with an elimination half-life of approximately 28 days. The 90-mg and 150-mg doses achieved median reductions in free factor XI (搜索) levels of 97% and 99%, respectively, at steady state. According to Weitz, "even patients who hold abelacimab for 60 days are likely to have residual drug activity before invasive procedures."
Despite this prolonged pharmacodynamic effect, bleeding (搜索) rates with abelacimab were comparable to those observed with rivaroxaban, which is typically discontinued 1-2 days before procedures. For the 55.8% of procedures that occurred within the dosing interval, no dose-response relationship was observed between the 90-mg and 150-mg abelacimab arms.
Bleeding Event Timeline and Management
The trial revealed reassuring safety data regarding bleeding (搜索) event timing. "There was no evidence of delayed bleeding," Weitz noted. "Most bleeding events occurred within 7 days of the procedure, and all occurred within 9 days." This finding addresses concerns about delayed bleeding complications given abelacimab's extended half-life.
Hemostatic therapies were required in only 5.1% of procedures, primarily involving tranexamic acid administration before or during procedures to minimize bleeding (搜索). No specific risk management strategies beyond standard care were employed, even for high-risk procedures.
Implications for Clinical Practice
The consistent bleeding (搜索) rates across different procedure types suggest that abelacimab's safety profile may not vary significantly based on surgical complexity. "There were no procedures associated with a disproportionately higher or lower rate of bleeding with abelacimab vs rivaroxaban," Weitz explained.
These findings could significantly impact clinical decision-making in outpatient settings. If confirmed in ongoing Phase 3 trials, the data suggest potential for streamlined periprocedural management protocols. "It may be possible to avoid abelacimab interruption in all but the highest bleeding (搜索) risk procedures," Weitz indicated.
Future Development and Protocol Considerations
Only the 150-mg abelacimab dose is advancing to Phase 3 evaluation, eliminating the need for dose-specific procedural planning recommendations. The research team emphasized that more information is needed for patients undergoing urgent procedures associated with high bleeding (搜索) risk.
The potential for protocol simplification represents a significant advancement in anticoagulation management. Current protocols typically require careful timing of anticoagulant interruption and resumption around procedures, creating complexity for both patients and healthcare providers. Abelacimab's profile may reduce this burden while maintaining safety standards.
If Phase 3 trials confirm these periprocedural safety findings, abelacimab could offer a paradigm shift in anticoagulation management, potentially allowing patients to maintain therapeutic anticoagulation through most procedures without increased bleeding (搜索) risk.